Although the prognosis for patients with diffuse large B-cell lymphoma is generally good with immediate treatment with the R-CHOP regiment, between 30% - 40% of patients still relapse and require additional treatment. Those patients with the activated B-cell (ABC) genetic subtype have a particularly poor prognosis. The industry has moved to address these needs, leading to rapid market evolution. Currently, there are than a dozen Phase 2 trails and half as many Phase 3 trials in progress for various combination and targeted therapies.


Fill in the form below to access an overview of our DLBCL syndicated study including:

  • Objectives 
  • Benefits
  • Samples
  • Scope
  • Types of data collected
  • Dates of research waves